Author + information
- Received September 30, 2014
- Revision received December 5, 2014
- Accepted December 18, 2014
- Published online May 1, 2015.
- Tommaso Gori, MD, PhD∗∗ (, )
- Eberhard Schulz, MD∗,
- Ulrich Hink, MD∗,
- Madeleine Kress∗,
- Nadja Weiers∗,
- Melissa Weissner∗,
- Alexander Jabs, MD∗,
- Philip Wenzel, MD∗,
- Davide Capodanno, MD, PhD† and
- Thomas Münzel, MD∗
- ∗2 Medizinische Klinik und Poliklinik–Kardiologie, Angiologie und Internistische Intensivmedizin, University Medical Center, Mainz, Germany
- †Ferrarotto Hospital, University of Catania, Catania, Italy
- ↵∗Reprint requests and correspondence:
Dr. Tommaso Gori, 2 Medizinische Klinik, University Medical Center Mainz, Langenbeckstrasse 1, 55131 Mainz, Germany.
Objectives The purpose of this study was to describe the multimodal outcome 12 months after implantation of coronary bioresorbable scaffolds (BVS) for the treatment of patients with acute coronary syndromes (ACS).
Background Functional and imaging data on the use of BVS are limited to simple, stable lesions; in the setting of ACS, only short-term clinical follow-up data are available, and no information from intracoronary imaging and vasomotion tests has been reported.
Methods A total of 133 patients (age 62 ± 12 years, 74% males, 15% diabetic) underwent BVS (n = 166) implantation for the treatment of thrombotic lesions in the setting of ACS (43% non–ST-segment elevation myocardial infarction, 38% ST-segment elevation myocardial infarction, 20% unstable angina). Clinical, angiographic, intracoronary imaging, and vasomotor endpoints were evaluated at 12 months.
Results During the 374 days (interquartile range: 359 to 411 days) of follow-up, there were 4 deaths; 3 definite and 1 probable in-BVS thromboses (all in the first 6 months). At 12-month angiography (75 patients, 83 BVS), in-segment late lumen loss was 0.19 ± 0.45 mm, and 3 (4%) patients showed binary restenosis. Optical coherence tomography (80 BVS, n = 70) showed a mean lumen area of 6.3 ± 2.3 mm2. Malapposition was evidenced in 21 (26%) BVS. Endothelium-dependent and -independent vasodilation were observed in 48% and 49% of the BVS.
Conclusions Twelve months after BVS implantation, clinical, intracoronary imaging, and vasomotion data appear to provide a rationale for the use of BVS in the setting of ACS and the basis for a randomized study.
Drs. Gori, Hink, and Münzel have received speaker fees from Abbott Vascular and/or St. Jude Medical. Dr. Schulz has held presentations for Abbott Vascular. Abbott Vascular had no role in any phase of this research. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received September 30, 2014.
- Revision received December 5, 2014.
- Accepted December 18, 2014.
- 2015 American College of Cardiology Foundation